Skip to main content
. Author manuscript; available in PMC: 2019 Mar 26.
Published in final edited form as: Nature. 2018 Sep 26;561(7724):479–484. doi: 10.1038/s41586-018-0531-2

Figure 1. Delayed viral rebound with 3BNC117 and 10–1074 combination therapy during ATI.

Figure 1.

a, Study design. Red and blue triangles represent 3BNC117 and 10–1074 infusions, respectively. b, Plasma HIV-1 RNA levels (black; left y-axis) and bNAb serum concentrations (3BNC117, red; 10–1074, blue; right y-axis) in the 9 bNAb-sensitive participants (left) and the 2 participants with pre-existing resistance against one of the antibodies (right). Red and blue triangles indicate 3BNC117 and 10–1074 infusions, respectively. Serum antibody concentrations were determined by TZM-bl assay. Grey shaded areas indicate time on ART. Lower limit of detection of HIV-1 RNA was 20 copies/ml. c, Kaplan-Meier plots summarizing time to viral rebound for the participants with HIV-1 RNA < 20 copies/ml 2 weeks before and at the start of ATI (n=11, left), for the participants sensitive to both antibodies (n=9, center), and for the participants that showed pre-existing resistance to one of the antibodies (n=2, right). Y-axis indicates percentage of participants that maintain viral suppression. X-axis indicates weeks after start of ATI. Participants receiving the combination of 3BNC117 + 10–1074 are indicated by the blue line. Dotted red lines indicate a cohort of individuals receiving 3BNC117 alone during ATI9 (n=13) and dotted black lines indicate a cohort of participants who underwent ATI without intervention10 (n=52).